CorporateEli Lilly Sues 6 US Sellers Over Black-Market Retatrutide, Calls Products ‘Unverified’BY Outlook Business Desk
CorporateNovo Nordisk Seeks US Court Order to Halt Eli Lilly's Weight-Loss Drug AdsBY Outlook Business Desk
CorporateOne Goal, 50 Brands: Inside the Scramble for India’s Post-Patent Semaglutide MarketBY Shashank Bhatt
CorporateNovo Nordisk Picks Emcure Pharma for Distribution of its Weight Loss InjectionBY Outlook Business Desk
CorporateNovo Nordisk Rolls-out Weight-Loss Jab Wegovy In India, Prices Higher Than Lilly's MounjaroBY Outlook Business Desk
